5,388 results match your criteria Overactive Bladder - Treatment


Validation of LC-MS/MS methods for the determination of mirabegron and eight metabolites in human plasma in a paediatric population.

J Pharm Biomed Anal 2019 Feb 7;167:155-160. Epub 2019 Feb 7.

Astellas Pharma Europe B.V., Leiden, The Netherlands.

Mirabegron is the first registered β3-adrenoceptor agonist for treatment of overactive bladder as an alternative to antimuscarinics. Previously four liquid chromatography-tandem mass spectrometry assays were published to determine mirabegron and eight metabolites (M5, M8, M11-M16) in human plasma. In order to support paediatric development, the assays were further optimized to reduce the required blood volume and increase the sensitivity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jpba.2019.02.007DOI Listing
February 2019

Exposure to antimuscarinic medications for treatment of overactive bladder and risk of lung cancer and colon cancer.

Clin Epidemiol 2019 23;11:133-143. Epub 2019 Jan 23.

Centre for Pharmacoepidemiology, Department of Medicine, Karolinska Institute, Solna, Sweden,

Introduction: One out of six adults has symptoms of overactive bladder (OAB). Antimuscarinic medication is the main pharmacological group used in the treatment of OAB. In preclinical studies, antimuscarinic compounds have been found to inhibit cell proliferation in lung cancer and colon cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CLEP.S186842DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6350836PMC
January 2019

How durable is the effect of mirabegron in successfully-treated overactive bladder patients? Analysis of a multicentre study.

Ceska Gynekol 2018 ;83(3):164-168

Objective: Many clinical studies indicate that pharmacologic treatment of overactive bladder (OAB) is considered effective and safe, but in real clinical practice a substantial proportion of patients discontinues the treatment. The reason for discontinuing the treatment most frequently reported is lack of efficacy and/or side effects. A further significant proportion of patients reports that they stopped the treatment because the symptoms disappeared or were resolved. Read More

View Article

Download full-text PDF

Source
January 2018

[Psychosomatic urology: how to treat chronic urological diseases].

Aktuelle Urol 2019 Feb 14. Epub 2019 Feb 14.

Ambulantes Rehabilitations-Zentrum für Urologie und Gynäkologie Heidelberg, Facharztpraxis für Urologie, Heidelberg.

In specialist urology clinics, 50 - 70 % of patients have chronic urological diseases such as recurrent urinary tract infections, a somatoform overactive bladder, adult and infantile enuresis, a chronic pelvic pain syndrome, and the psychosomatic form of post-prostatectomy incontinence. The 12-month prevalence of psychological disorders in the general adult population is 28 % 1. As many as 20 % of children and adolescents are found to have psychological abnormalities 2. Read More

View Article

Download full-text PDF

Source
http://www.thieme-connect.de/DOI/DOI?10.1055/a-0834-5989
Publisher Site
http://dx.doi.org/10.1055/a-0834-5989DOI Listing
February 2019
1 Read

[A role of fesoterodine in treatment of overactive bladder].

Urologiia 2018 Dec(6):155-162

Department of Urology of Federal State Budgetary Educational Institution of Higher Education A.I. Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Healthcare of the Russian Federation, Moscow, Russia.

The muscarinic receptors have been used as target in treatment of overactive bladder (OAB) for a long time. These patients have complaints of urgency, increased urinary frequency and nocturia, sometimes with urinary incontinence (involuntary urine leakage which is associated with abrupt and strong desire to void). Fesoterodine is a prodrug that is structurally and functionally associated with tolterodine and it is the novel drug for OAB treatment. Read More

View Article

Download full-text PDF

Source
December 2018

[Imidafenacin for treatment of overactive bladder and urgent urinary incontinence: the results of open-label multicenter randomized controlled clinical trial].

Urologiia 2018 Dec(6):20-25

FGBOU VO Pavlov First Saint Petersburg State Medical University of Minzdrav of Russia, Saint Petersburg, Russia.

Introduction: The analysis of the results of a multicenter, open, randomized comparative phase III clinical trial on the use of imidafenacin for treating patients with OAB was carried out. A clinical study was conducted according to GCP standards in 12 urological centers of the Russian Federation with the support of company AO "R-Pharm".

Materials And Methods: A total of 296 patients (men and women) aged from 18 to 65 years with OAB and urgent urinary incontinence were included in the study. Read More

View Article

Download full-text PDF

Source
December 2018

[Analisys of non-neurogenic lower urinary tract dysfunction patterns controlled in a Pediatric urodynamic unit.]

Arch Esp Urol 2019 Jan;72(1):45-53

Hospital Materno Infantil Teresa Herrera. A Coruña. España.

Objectives: Between 7-10% of schoolagechildren are seen by specialists for non-neurogeniclower urinary tract dysfunction (LUTD). The objective ofour study is to classify these functional alterations in difused for the diagnosis and treatment in each pattern.

Material And Methods: We reviewed patients referredto our Urodynamic Unit for suspected LUTD for3 years; We reviewed epidemiological data, supplementarytest and treatments. Read More

View Article

Download full-text PDF

Source
January 2019
1 Read

How to assess and predict success or failure of intra-detrusor injections with onabotulinumtoxinA.

Adv Clin Exp Med 2019 Feb 5. Epub 2019 Feb 5.

Department of Urology, Jagiellonian University Medical College, Kraków, Poland.

Intra-detrusor injection therapy with onabotulinumtoxinA is generally accepted as a highly effective, minimally invasive and well-tolerated day procedure for patients with refractory overactive bladder (OAB) and neurogenic detrusor overactivity (NDO). The aim of this study was to summarize currently available methods of assessing treatment efficacy and risk factors that may influence the therapeutic effect of this approach. We found that there are discrepancies in the assessment methods. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.17219/acem/90764DOI Listing
February 2019

Which antimuscarinic agents used in the treatment of overactive bladder increase heart rate? a prospective randomized clinical trial.

Int Urol Nephrol 2019 Feb 6. Epub 2019 Feb 6.

Department of Urology, Bagcilar Training and Research Hospital, University of Health Sciences, Istanbul, Turkey.

Purpose: To compare the heart rate increase side effect of different antimuscarinic drugs used in overactive bladder (OAB).

Methods: Overall 341 patients were consecutively randomized to take seven different antimuscarinic drugs between January 2014 and June 2016 at three institutions, and 250 patients who completed the follow-up visits were accepted into this study. Ninety-one patients who never came to visits were excluded. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11255-019-02090-9DOI Listing
February 2019
1 Read

Antimuscarinic drug therapy for overactive bladder syndrome in the elderly - are the concerns justified?

Authors:
Jay Khastgir

Expert Opin Pharmacother 2019 Feb 6:1-8. Epub 2019 Feb 6.

a Swansea University Medical School , Abertawe Bro Morganwwg University Health Board , Swansea , Wales , UK.

Introduction: The use of antimuscarinic drugs is common in the management of the overactive bladder (OAB). Concerns have been raised over their use in the elderly population in whom the use of these drugs is highly prevalent, consequent to the reported link between these drugs and cognitive impairment and dementia. Areas covered: Recent publications have heightened concerns regarding antimuscarinic drug use in the elderly. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14656566.2019.1574749DOI Listing
February 2019
1 Read

Characterizing the Health-Related Quality of Life Burden of Overactive Bladder Using Disease-Specific Patient-Reported Outcome Measures: A Systematic Literature Review.

Adv Ther 2019 Feb 4. Epub 2019 Feb 4.

Broadstreet Health Economics and Outcomes Research, Vancouver, BC, Canada.

Introduction: The objective was to identify the most commonly used patient-reported outcome (PRO) instruments for overactive bladder (OAB), determine which are the most useful for measuring burden in OAB and characterize the findings of recent studies that have employed PRO instruments to assess OAB symptoms and the effects of treatment.

Methods: A systematic search of OAB literature published between January 2006 and November 2017 using Medline/PubMed and EMBASE databases.

Results: Of 3425 abstracts and 500 full-text articles reviewed, 58 studies (both clinical trials and observational studies) were included in the review. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12325-019-0880-8DOI Listing
February 2019
1 Read

Effect of mirabegron on tight junction molecules in primary cultured rat Sertoli cells.

Andrologia 2019 Jan 31:e13241. Epub 2019 Jan 31.

Division of Urology, Kobe University Graduate School of Medicine, Kobe, Japan.

Mirabegron is a selective beta3-adrenoceptor (β -AR) agonist, which is commonly used for the treatment of overactive bladder. This medicine is associated with atrophy of reproductive organs in rats. However, no study has examined the detailed action and mechanism of its toxicity in reproductive cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/and.13241DOI Listing
January 2019
1 Read

Evaluation of real-world persistence of propiverine and trospium chloride in treatment of overactive bladder in Germany.

Res Rep Urol 2019 17;11:9-13. Epub 2019 Jan 17.

StatConsult Gesellschaft für klinische und Versorgungsforschung mbH, Magdeburg, Germany.

Treatment persistence poses a crucial criterion for therapeutic success. Like in many other chronic diseases, in overactive bladder (OAB) syndrome also, many patients discontinue their treatment for diverse reasons. In order to evaluate the persistence in medication, this paper presents data of propiverine extended release (ER) and trospium chloride immediate release (IR) for three consecutive quarters, thus giving an insight into the probability of treatment discontinuation for these two drugs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/RRU.S185278DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6342142PMC
January 2019

Do Patients Discontinue Overactive Bladder Medications After Sacral Neuromodulation?

J Urol 2019 Jan 25. Epub 2019 Jan 25.

Introduction: Overactive bladder (OAB) medications often have poor tolerability or lack of efficacy with many progressing to 3 line therapy, such as sacral neuromodulation (SNM). Use of SNM may avoid the potential side effects of OAB medications, while achieving symptom improvement. We evaluated the post-operative rate of discontinuing OAB medications in patients who underwent SNM for refractory OAB. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JU.0000000000000035DOI Listing
January 2019

On the Absolute Stereochemistry of Tolterodine: A Circular Dichroism Study.

Pharmaceuticals (Basel) 2019 Jan 26;12(1). Epub 2019 Jan 26.

Dipartimento di Chimica e Chimica Industriale, Università di Pisa, Via Moruzzi 13, 56124 Pisa, Italy.

Tolterodine () is a potent muscarinic receptor antagonist used in the treatment of overactive urinary bladder (OAB) syndrome. Tolterodine is chiral and it was patented, and is currently marketed, as the l-tartrate salt of the ()-enantiomer. However, the existing literature does not offer an ultimate proof of a stereoselective mode of action of . Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/ph12010021DOI Listing
January 2019

NOP-Targeted Peptide Ligands.

Handb Exp Pharmacol 2019 Jan 29. Epub 2019 Jan 29.

Department of Chemical and Pharmaceutical Sciences, University of Ferrara, Ferrara, Italy.

The nociceptin/orphanin FQ (N/OFQ)-N/OFQ peptide (NOP) receptor system is widely distributed at both the peripheral and central level where it modulates important biological functions with increasing therapeutic implications. This chapter wants to provide a comprehensive and updated overview focused on the available structure-activity relationship studies on NOP receptor peptide ligands developed through different rational approaches. Punctual modifications and cyclizations of the N/OFQ sequence have been properly combined furnishing potent NOP selective ligands with different pharmacological activities (full and partial agonists, pure antagonists) and enhanced metabolic stability in vivo. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/164_2018_198DOI Listing
January 2019
2 Reads

Efficacy and safety of non-ablative vaginal erbium:YAG laser treatment as a novel surgical treatment for overactive bladder syndrome: comparison with anticholinergics and β3-adrenoceptor agonists.

Authors:
Nobuo Okui

World J Urol 2019 Jan 28. Epub 2019 Jan 28.

Uro-Gyn.Net Health Care Cooperation, Dr. Okuis' Urogynecology and Urology Clinic, Ootaki 2-6, Yokosuka, Kanagawa, 238-0008, Japan.

Purpose: To examine the efficacy and safety of non-ablative vaginal erbium:YAG laser (VEL) for the treatment of overactive bladder syndrome (OAB) compared with those of two other common pharmacotherapies, namely, anticholinergics and β3-adrenoceptor agonists.

Methods: Female subjects aged 60-69 years who presented with symptoms of OAB from 2015 to 2017 were assigned to three groups (n = 50) receiving treatment with an anticholinergic agent (4 mg fesoterodine), a β3-adrenoceptor agonist (25 mg mirabegron), or VEL (20 min/session of VEL performed thrice). The OAB symptom score (OABSS), Vaginal Health Index Scale (VHIS), and occurrence of adverse effects were examined prior to and at 1 year following treatment initiation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00345-019-02644-7DOI Listing
January 2019
1 Read

Need for urodynamic evaluation as a regular follow-up tool in assessment of long-term urological outcomes in patients with sacrococcygeal teratoma.

J Pediatr Surg 2018 Dec 29. Epub 2018 Dec 29.

Department of Pediatric Surgery, All India Institute of Medical Sciences, New Delhi 110029, India.

Aim: To assess the long-term urologic outcomes in follow-up of patients of sacrococcygeal teratoma (SCT) using urodynamic study (UDS) in addition to clinical and radiologic evaluation.

Methods: A prospective study of clinical, radiological and urodynamic evaluation in patients with SCT who underwent resection between January 2002-June 2015 and were followed up till January 2016 was conducted.

Results: Total 57 patients, 42 (73. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jpedsurg.2018.11.020DOI Listing
December 2018
1 Read

Pathways to causation and surgical cure of chronic pelvic pain of unknown origin, bladder and bowel dysfunction - an anatomical analysis.

Cent European J Urol 2018 27;71(4):448-452. Epub 2018 Dec 27.

FA für Gynäkologie, Geburtshilfe und Chirurgie, Akademisches Lehrkrankenhaus, Feldkirch, Austria.

Introduction: Current thinking is that chronic pelvic pain of unknown origin (CPPU) is poorly understood and its treatment is empirical and ineffective. According to the Integral Theory System (ITS), however, CPPU is secondary to uterosacral ligament (USL) laxity which is associated with bladder and bowel symptoms and all are potentially curable by surgical reinforcement of USLs.

Material And Methods: We applied the ITS to anatomically explain the pathogenesis and cure of these conditions. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5173/ceju.2018.1807DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6338817PMC
December 2018
1 Read

Comparison of Oxidative Effects of Two Different Administration Form of Oxybutynin in the Potential Target Tissues.

Adv Urol 2018 24;2018:8124325. Epub 2018 Dec 24.

Biology Department, Science Faculty, Gazi University, 06500 Ankara, Turkey.

Oxybutynin is an important anticholinergic agent that prevents uncontrolled contractions in the treatment of overactive bladder (OAB). However, drugs containing oxybutynin have significant side effects such as dry eyes, dry mouth, increased heart rate, constipation, blurred vision, and confusion. In recent years, new delivery methods for this agent are being searched. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2018/8124325DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6323524PMC
December 2018
2 Reads

The impact of Mirabegron on sexual function in women with idiopathic overactive bladder.

BMC Urol 2019 Jan 21;19(1). Epub 2019 Jan 21.

Department of Obstetrics and Gynecology, University of Insubria, Varese, 21100, Italy.

Background: Overactive bladder (OAB) can frequently exert a negative effect on female sexual function. Mirabegron, a β3 receptor agonist, improves OAB symptoms, but there are very few information about its role on female sexual dysfunction (FSD). Aim of the study was to assess the impact of Mirabegron on FSD in women affected by OAB. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12894-019-0438-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6341751PMC
January 2019
3 Reads

Vibegron (RVT-901/MK-4618/KRP-114V) Administered Once Daily as Monotherapy or Concomitantly with Tolterodine in Patients with an Overactive Bladder: A Multicenter, Phase IIb, Randomized, Double-blind, Controlled Trial.

Eur Urol 2019 Feb 25;75(2):274-282. Epub 2018 Oct 25.

Merck & Co., Inc., Kenilworth, NJ, USA. Electronic address:

Background: Antimuscarinics have shown modest efficacy with unwanted side effects in patients with overactive bladder (OAB). Efficacy of vibegron, a new β3-adrenergic receptor agonist, for OAB is unknown.

Objective: To evaluate the efficacy of once-daily oral vibegron in OAB patients (primary), and its safety, tolerability, and efficacy when administered alone or concomitantly with tolterodine (secondary). Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S03022838183074
Publisher Site
http://dx.doi.org/10.1016/j.eururo.2018.10.006DOI Listing
February 2019
3 Reads

Repeatability of tools to assist in the follow up and troubleshooting of sacral neuromodulation patients using the sensory response.

Neurourol Urodyn 2019 Jan 15. Epub 2019 Jan 15.

Department of Urology, Antwerp University Hospital (UZA), Edegem, Belgium.

Purpose: Sacral neuromodulation (SNM) is an established minimally invasive therapy for functional disorders of the pelvic organs in which electrodes are stimulated in proximity of the sacral spinal nerves. Reprogramming of the electrodes is regularly required and is based on the sensory response. This study assesses the repeatability of a pelvic chart and grading system to enable a more objective assessment of the sensory response upon electrode stimulation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/nau.23925DOI Listing
January 2019
1 Read

Long-term treatment of older patients with overactive bladder using a combination of mirabegron and solifenacin: a prespecified analysis from the randomized, phase III SYNERGY II study.

Neurourol Urodyn 2019 Jan 15. Epub 2019 Jan 15.

University of Munich, Munich, Germany.

Aims: SYNERGY II was a 12-month phase III trial in patients with overactive bladder (OAB) symptoms that investigated the safety and efficacy of the combination of mirabegron and solifenacin in comparison with each monotherapy. This analysis evaluated the trial findings using four age subgroups (<65, ≥65, <75, and ≥75 years).

Methods: Eligible patients were ≥18 years with symptoms of "wet" OAB (urinary frequency and urgency with incontinence) for ≥3 months. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/nau.23919DOI Listing
January 2019
1 Read

Clinical relevance and treatment outcomes of vesicovaginal fistula (VVF) after obstetric and gynecologic surgery.

Taiwan J Obstet Gynecol 2019 Jan;58(1):111-116

Fellow, Division of Urogynaecology, Department of Obstetrics and Gynaecology, Chang Gung Memorial Hospital, Linkou Medical Center, Taoyuan, Taiwan, Republic of China; Department of Obstetrics and Gynecology, Dr. Pablo O. Torre Memorial Hospital, Bacolod City, Philippines.

Objective: Vesicovaginal fistulas (VVF) are consequences from obstetric and gynecologic surgery. Treatment approach from either abdominal or vaginal route have its own pros and cons. The study aims to present the anatomical, clinical and lower urinary tract symptom outcomes of women with VVF. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.tjog.2018.11.021DOI Listing
January 2019
1 Read

Transvaginal ultrasound guided trigone and bladder injection: A cadaveric feasibility study for a novel route of intradetrusor chemodenervation.

Investig Clin Urol 2019 Jan 24;60(1):40-45. Epub 2018 Dec 24.

Department of Urology, Stanford University School of Medicine, Stanford, CA, USA.

Purpose: OnabotulinumtoxinA (BTX) detrusor chemodenervation is an efficacious third-line treatment for overactive bladder. Despite high clinical efficacy rates for BTX injection, many patients refuse initial or repeat treatment due to the invasiveness of the cystoscopic route of delivery. We assess the feasibility of injecting the trigone and posterior bladder wall via a transvaginal route under ultrasound guidance using a human cadaveric model. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4111/icu.2019.60.1.40DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6318206PMC
January 2019
1 Read

Understanding overactive bladder and urgency incontinence: what does the brain have to do with it?

Authors:
Ariana L Smith

F1000Res 2018 29;7. Epub 2018 Nov 29.

Division of Urology, University of Pennsylvania , Philadelphia, PA, USA.

Understanding the pathophysiologic mechanisms responsible for overactive bladder (OAB) and urgency urinary incontinence (UUI) is critical to advancing the treatment options available to men and women with this prevalent and bothersome condition. Development of novel technologies and advanced functional neuroimaging modalities has provided us with new information to support and refine existing mechanistic theories. Emerging research on central pathophysiologic mechanisms of OAB from functional magnetic resonance imaging may provide new targets for therapeutic interventions and opens the door for novel treatment strategies. Read More

View Article

Download full-text PDF

Source
https://f1000research.com/articles/7-1869/v1
Publisher Site
http://dx.doi.org/10.12688/f1000research.16418.1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6281005PMC
November 2018
10 Reads

Mirabegron: A Novel and Promising Medical Expulsive Treatment for Ureteral Stones?

J Coll Physicians Surg Pak 2019 Jan;29(1):73-74

Department of Urology, Bahcesehir University, VM Medical Park Hospital, Istanbul, Turkey.

Medical expulsive therapy (MET) is used especially in distal ureteral stones to reduce colics and decrease the number of endourological surgical interventions. A broad spectrum of agents can be used for the relaxation and the dilatation of the ureter, reducing the intraureteric pressure. Alfa-blockers, calcium channel blockers, phosphodiesterase (PDE) inhibitors, and spasmolytics have been shown as effective in clinical trials on urolithiasis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.29271/jcpsp.2019.01.73DOI Listing
January 2019
1 Read

Effectiveness and persistence of mirabegron as a first-line treatment in patients with overactive bladder in real-life practice.

Low Urin Tract Symptoms 2019 Jan 8. Epub 2019 Jan 8.

Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.

Objectives: To evaluate the effectiveness and persistence of mirabegron as a first-line treatment in patients with overactive bladder (OAB) in real-life practice.

Methods: We retrospectively analyzed patients with OAB who received mirabegron (50 mg) as a first-line treatment. According to treatment course, patients were divided into three groups, (a) mirabegron only (monotherapy group), (b) mirabegron and anticholinergics (add-on group), and (c) mirabegron replaced with another treatment (switch group). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/luts.12253DOI Listing
January 2019

[Use of botulinum toxin A in pelvic floor dysfunctions in the elderly: A review].

Prog Urol 2019 Jan 5. Epub 2019 Jan 5.

Groupe de recherche appliquée à la pathologie pelvi-périnéale des personnes âgées (GRAPPPA), 75020 Paris, France.

Introduction: The present article is the final report of a multi-disciplinary meeting supported by the GRAPPPA (group for research applied to pelvic floor dysfunctions in the elderly). The objective was to conduct a comprehensive review on the role of botulinum toxin A (BonTA) in the treatment of pelvic floor dysfunctions in the elderly.

Methods: The present article, written as a comprehensive review of the literature, combines data issued from the scientific literature with expert's opinions. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.purol.2018.11.001DOI Listing
January 2019
3 Reads

Comparative effectiveness of one versus two-stage sacral neurostimulation device placement.

Neurourol Urodyn 2019 Jan 8. Epub 2019 Jan 8.

Cedars Sinai Medical Center, Division of Urology Los Angeles, Los Angeles, California.

Objective: Sacral neurostimulation (SNS) is an effective third-line treatment for overactive bladder. We sought to compare the cost of standard two-stage SNS device placement to that of a combined one-stage placement using a Markov chain model.

Methods: Costs were defined using Medicare outpatient reimbursement rates. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/nau.23908
Publisher Site
http://dx.doi.org/10.1002/nau.23908DOI Listing
January 2019
4 Reads

Fundamentals of urodynamic practice, based on International Continence Society good urodynamic practices recommendations.

Neurourol Urodyn 2018 Aug;37(S6):S50-S60

Bristol Urological Institute, Southmead Hospital, Bristol, UK.

Aims: To review the recommendations on basic urodynamic testing in the International Continence Society (ICS) standardization documents, specifying key recommendations for delivery and interpretation in clinical practice.

Methods: Fundamental expectations described in the ICS standards on good urodynamic practices, urodynamic equipment, and terminology for lower urinary tract (LUT) function were identified and summarized.

Results: The ICS standard urodynamic protocol includes clinical history, including symptom and bother score(s), examination, 3-day voiding chart/diary, representative uroflowmetry with post-void residual, and cystometry with pressure-flow study (PFS). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/nau.23773DOI Listing

The Value of Ambulatory Urodynamics in the Evaluation of Treatment Effect of Sacral Neuromodulation.

Urol Int 2019 Jan 4:1-7. Epub 2019 Jan 4.

Department of Urology, Maastricht University Medical Centre (MUMC+), Maastricht, The Netherlands.

Objectives: To assess the improvement of symptoms by sacral neuromodulation (SNM) in an objective way by carrying out an ambulatory urodynamic study (ambulatory-UDS). Until now, successful treatment has been defined as a ≥50% improvement recorded on voiding diaries. Voiding diaries are a patient reported outcome tool. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000493988DOI Listing
January 2019
1 Read

Results of Sacral Neuromodulation Therapy for Urinary Voiding Dysfunction: Five-Year Experience of a Retrospective, Multicenter Study in China.

Neuromodulation 2019 Jan 4. Epub 2019 Jan 4.

Department of Urology, West China Hospital, Sichuan University, Chengdu, P.R. China.

Purpose: This five-year, retrospective, multicenter study evaluated the long-term safety and efficiency of sacral neuromodulation (SNM) in Chinese patients with urinary voiding dysfunction.

Patients And Methods: This is a Chinese national, multicenter, retrospective study that included 247 patients (51.2% female) who received an implantable pulse generator (IPG) (InterStim, Medtronic, Minneapolis, MN, USA) between 2012 and 2016. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ner.12902DOI Listing
January 2019
1 Read

Post-Marketing Surveillance of Silodosin in Patients with Benign Prostatic Hyperplasia and Poor Response to Existing Alpha-1 Blockers: The SPLASH Study.

Drugs R D 2019 Jan 3. Epub 2019 Jan 3.

Department of Urology, National Center for Geriatrics and Gerontology, Obu, Japan.

Objectives: Our objective was to investigate the effectiveness and safety of silodosin in patients with benign prostatic hyperplasia (BPH) who switched to silodosin from another α blocker because of inadequate response.

Methods: This was a prospective observational study conducted at 715 medical facilities in Japan in patients with BPH who received an α blocker other than silodosin for at least 3 months but had experienced unsatisfactory treatment outcomes. Patients completed questionnaires, including the International Prostate Symptom Score (IPSS), quality of life (QOL) score and Overactive Bladder Symptom Score (OABSS) at baseline (time of switching) and after 3 months of treatment with silodosin. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40268-018-0258-4DOI Listing
January 2019
1 Read

Overactive urinary bladder in elderly female patients: treatment specificities and drug interactions.

Vnitr Lek 2018 ;64(11):1085-1090

Aging is an inevitable process in the life of each organism and it is no different in the human world. According to the world statistics and demographic data, an ever increasing group in our population live to a ripe old age. The paper deals with pharmacological therapy for overactive bladder (OAB) in older women while also considering frequent comorbidities in older age. Read More

View Article

Download full-text PDF

Source
January 2018
4 Reads

BCG Therapy for Type 1 Diabetes: Restoration of Balanced Immunity and Metabolism.

Trends Endocrinol Metab 2019 Feb 29;30(2):80-92. Epub 2018 Dec 29.

Department of Medicine, Immunobiology Laboratories, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA. Electronic address:

The bacillus Calmette-Guerin (BCG) vaccine is a microorganism developed as a vaccine for tuberculosis 100 years ago and used as therapy for bladder cancer 40 years ago. More recently, BCG has shown therapeutic promise for type 1 diabetes (T1D) and several other autoimmune diseases. In T1D, BCG restored blood sugars to near normal, even in patients with advanced disease of >20 years duration. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.tem.2018.11.006DOI Listing
February 2019
1 Read

Prevalence, Risk Factors, and Treatment for Overactive Bladder in a Racially Diverse Population.

Urology 2018 Dec 28. Epub 2018 Dec 28.

Department of Urology, Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, NY. Electronic address:

Objective: To evaluate differences in prevalence, overactive bladder (OAB) risk factors, and OAB treatment in a diverse population of underrepresented racial/ethnic groups.

Methods: This is a retrospective cohort study of women ≥ 18 years who had an OAB diagnosis code from June 1, 2013 to June 30, 2016. Women who had neurogenic bladder or pelvic cancer were excluded. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urology.2018.12.021DOI Listing
December 2018
1 Read

Effectiveness of neuromuscular electrical stimulation therapy in patients with urinary incontinence after stroke: A randomized sham controlled trial.

Medicine (Baltimore) 2018 Dec;97(52):e13702

Department of Neurology, The First People's Hospital of Xianyang City, Xianyang, China.

Background: This study aimed to evaluate the effectiveness of neuromuscular electrical stimulation (NMES) therapy in patients with urinary incontinence after stroke (UIAS).

Methods: A total of 82 patients with UIAS were randomly assigned to 2 groups that received NMES therapy (NMES group) or sham NMES (sham group) for 10 weeks. The primary efficacy endpoints were measured by urodynamic values, and Overactive Bladder Symptom Score (OABSS). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000013702DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6314727PMC
December 2018
1 Read

Novel immediate/sustained-release formulation of acetaminophen-ibuprofen combination (Paxerol®) for severe nocturia associated with overactive bladder: A multi-center, randomized, double blinded, placebo-controlled, 4-arm trial.

Neurourol Urodyn 2018 Dec 28. Epub 2018 Dec 28.

SUNY Downstate College of Medicine, Department of Urology, Brooklyn, New York.

Aim: To determine short-term efficacy and safety of Paxerol®, novel immediate:sustained (50%:50%) release tablets containing 325 mg acetaminophen and 150 mg ibuprofen per tablet.

Methods: One of three dose levels, corresponding to the amounts in 1, 2, and 3 tablets, of Paxerol and placebo were administered for 14 consecutive days to patients with severe nocturia (defined in this study as an average nocturnal voids [NV] ≥2.5) associated with overactive bladder (OAB). Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/nau.23910
Publisher Site
http://dx.doi.org/10.1002/nau.23910DOI Listing
December 2018
12 Reads

A prospective, multicenter study of a novel, miniaturized rechargeable sacral neuromodulation system: 12-month results from the RELAX-OAB study.

Neurourol Urodyn 2018 Dec 28. Epub 2018 Dec 28.

Department of Uro-Neurology, National Hospital of Neurology and Neurosurgery, London, United Kingdom.

Aims: Historically, providing SNM therapy required use of a non-rechargeable implantable pulse generator (IPG) with an average device lifespan of 4.4 years. Multiple device replacement surgeries are necessary with this device for long-term overactive bladder (OAB) management. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/nau.23892
Publisher Site
http://dx.doi.org/10.1002/nau.23892DOI Listing
December 2018
10 Reads

Positive Association of Male Overactive Bladder Symptoms and Androgen Deprivation: A Nationwide Population-based Cohort Study.

Anticancer Res 2019 Jan;39(1):305-311

Division of Urology, Department of Surgery, Taichung Veterans General Hospital, Taichung, Taiwan, R.O.C.

Background/aim: The role of androgen in the modulation of voiding function is still uncertain. The aim of this study was to evaluate the association of androgen deprivation therapy (ADT) and overactive bladder (OAB) in men in a population-based cohort.

Materials And Methods: This study examined the records of newly-diagnosed prostate cancer subjects receiving ADT only in the Taiwan National Health Insurance Research Database in the years between 2001 and 2007. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.13112DOI Listing
January 2019
2 Reads
1.872 Impact Factor

The effect of body mass index on retropubic midurethral slings.

Am J Obstet Gynecol 2018 Dec 18. Epub 2018 Dec 18.

Birmingham Women's Hospital, Birmingham, UK.

Background: Analyzing surgical databases uses "real-life" outcomes rather than highly selected cases from randomized controlled trials. Retropubic midurethral slings are a highly effective surgical treatment for stress urinary incontinence; however, if modifiable patient characteristics alter outcomes, thereby rendering treatments less effective, patients should be informed and given the opportunity to change that characteristic.

Objective: The aim of this study was to evaluate the effect of body mass index on patient-reported outcome measures by analyzing midurethral slings from the British Society of Urogynaecology database. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ajog.2018.12.018DOI Listing
December 2018
2 Reads

Which anticholinergic is best for people with overactive bladders? A network meta-analysis.

Neurourol Urodyn 2018 Dec 21. Epub 2018 Dec 21.

School of Public Health and Preventive Medicine, Monash University, level 6, The Alfred Centre, Melbourne, Victoria, Australia.

Aim: To carry out a network meta-analysis of randomised controlled trials (RCTs) of anticholinergic drug treatment for people with overactive bladders.

Methods: Comprehensive searches for relevant RCTs were carried out starting with RCTs included in previous systematic reviews with the last search in February 2017. Searches included terms for the anticholinergic drugs tolterodine, oxybutynin, trospium, propiverine, solifenacin, darifenacin, imidafenacin, and fesoterodine. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/nau.23893DOI Listing
December 2018

[New approach to the treatment of patients with overactive bladder. Mirabegron: past, present and future].

Authors:
E S Korshunova

Urologiia 2018 Dec(5):170-174

FGBU National Medical Research Radiology Center of the Ministry of Health of Russia, Moscow, Russia.

The prevalence rate of overactive bladder symptoms is 16% for men and 16.9% for women. Currently, m-anticholinergics are the first line of therapy. Read More

View Article

Download full-text PDF

Source
December 2018

Mirabegron, alone and in combination, in the treatment of overactive bladder: real-world evidence and experience.

Ther Adv Urol 2018 Dec 26;10(12):411-419. Epub 2018 Sep 26.

Division of Geriatric Medicine, University of Alberta, 1-198 Clinical Sciences Building, 11350 83Ave, Edmonton, Alberta, T6G 2P4, Canada.

Overactive bladder (OAB), the syndrome characterized by urgency, with or without urgency incontinence, usually with frequency and nocturia, in the absence of infection or other pathology, is a common, distressing and often debilitating condition with a high prevalence in the general population. For many years, the only available pharmacological treatment for OAB were the antimuscarinic agents. More recently, mirabegron, a selective agonist of the β3 adrenergic receptor, has become available. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1756287218801282DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6295783PMC
December 2018
1 Read

Higher urge severity score predicts resumption of overactive bladder (OAB) medication following discontinuation of mirabegron treatment in patients with OAB.

Low Urin Tract Symptoms 2018 Dec 18. Epub 2018 Dec 18.

Department of Urology, Buddhist Tzu Chi General Hospital and Tzu Chi University, Hualien, Taiwan.

Objectives: This study investigated factors predicting the resumption of mirabegron following its discontinuation with successful treatment of overactive bladder (OAB).

Methods: In all, 374 OAB patients reporting an improvement in subjective symptoms after a minimum of 3 months treatment with mirabegron 25 mg, q.d. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/luts.12252DOI Listing
December 2018

Introital ultrasound in the diagnosis of lower urinary tract symptoms following anti-incontinence surgery using a synthetic midurethral tape.

Int Urogynecol J 2018 Dec 18. Epub 2018 Dec 18.

Department of Urology, Medical University of Gdansk, Gdansk, Poland.

Introduction And Hypothesis: Surgical treatment of stress urinary incontinence in women using a synthetic midurethral tape has become a standard procedure. One of the complications observed postoperatively are lower urinary tract symptoms (LUTS). The aim was to analyze the role of introital ultrasound in the identification of patients at risk for developing LUTS after surgical treatment using synthetic tape. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00192-018-3837-6DOI Listing
December 2018
2 Reads

Urothelial Senescence in the Pathophysiology of Diabetic Bladder Dysfunction-A Novel Hypothesis.

Front Surg 2018 4;5:72. Epub 2018 Dec 4.

Department of Physiology, Medical College of Georgia at Augusta University, Augusta, GA, United States.

Diabetic bladder dysfunction (DBD) is a well-recognized and common symptom affecting up to 50% of all diabetic patients. DBD has a broad range of clinical presentations ranging from overactive to underactive bladder symptoms that develops in middle-aged to elderly patients with long standing and poorly controlled diabetes. Low efficacy of current therapeutics and lifestyle interventions combined with high national healthcare costs highlight the need for more research into bladder dysfunction pathophysiology and novel treatment options. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fsurg.2018.00072DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6288180PMC
December 2018